Covid-19: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tag: Suntingan perangkat seluler Suntingan aplikasi seluler Suntingan aplikasi Android |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.8 |
||
Baris 129:
[[Steroid]], seperti [[metilprednisolon]], tidak dianjurkan kecuali penyakitnya dipersulit oleh [[sindrom gangguan pernapasan akut]] (ARDS).<ref>{{Cite journal|last=Vetter|first=Pauline|last2=Eckerle|first2=Isabella|last3=Kaiser|first3=Laurent|date=2020-02-19|title=Covid-19: a puzzle with many missing pieces|url=http://www.bmj.com/lookup/doi/10.1136/bmj.m627|journal=BMJ|language=en|pages=m627|doi=10.1136/bmj.m627|issn=1756-1833}}</ref><ref>{{Cite web|url=https://www.ebmedicine.net/topics/infectious-disease/COVID-19,%20https://www.ebmedicine.net/topics/infectious-disease/COVID-19|title=Novel Coronavirus—COVID-19: What Emergency Clinicians Need to Know|last=|first=|date=2020-03-23|website=EBMEDICINE|language=en|access-date=2020-05-06}}</ref>
[[Perhimpunan Imunologi Klinis dan Alergi Australasia]] merekomendasikan bahwa [[tosilizumab]] perlu dipertimbangkan sebagai pilihan pengobatan bagi mereka yang mengalami ARDS yang terkait dengan COVID-19. Rekomendasi ini dilakukan karena obat ini diketahui bermanfaat dalam [[badai sitokin]] yang disebabkan oleh [[Sel T reseptor antigen kimerik|pengobatan kanker tertentu]], dan bahwa badai sitokin mungkin merupakan kontributor signifikan terhadap kematian pada COVID-19 yang berat.<ref>{{Cite web|url=https://allergy.org.au/hp/papers/specific-treatments-for-covid-19|title=ASCIA Position Statement: Specific Treatments for COVID-19|last=Grainger|first=Suzanne|website=Australasian Society of Clinical Immunology and Allergy (ASCIA)|language=en-gb|access-date=2020-05-06|archive-date=2020-06-16|archive-url=https://web.archive.org/web/20200616150611/https://allergy.org.au/hp/papers/specific-treatments-for-covid-19|dead-url=yes}}</ref>
Obat untuk mencegah pembekuan darah juga disarankan,<ref>{{Cite journal|last=Klok|first=F.A.|last2=Kruip|first2=M.J.H.A.|last3=van der Meer|first3=N.J.M.|last4=Arbous|first4=M.S.|last5=Gommers|first5=D.A.M.P.J.|last6=Kant|first6=K.M.|last7=Kaptein|first7=F.H.J.|last8=van Paassen|first8=J.|last9=Stals|first9=M.A.M.|date=2020-04|title=Incidence of thrombotic complications in critically ill ICU patients with COVID-19|url=https://linkinghub.elsevier.com/retrieve/pii/S0049384820301201|journal=Thrombosis Research|language=en|pages=S0049384820301201|doi=10.1016/j.thromres.2020.04.013|pmc=PMC7146714|pmid=32291094}}</ref> dan terapi [[antikoagulan]] menggunakan [[heparin]] dengan berat molekul rendah dihubungkan dengan hasil yang lebih baik pada penderita COVID-19 berat, yang menunjukkan tanda-tanda [[koagulopati]] (peningkatan [[D-dimer]]).<ref>{{Cite journal|last=Tang|first=Ning|last2=Bai|first2=Huan|last3=Chen|first3=Xing|last4=Gong|first4=Jiale|last5=Li|first5=Dengju|last6=Sun|first6=Ziyong|date=2020-05|title=Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14817|journal=Journal of Thrombosis and Haemostasis|language=en|volume=18|issue=5|pages=1094–1099|doi=10.1111/jth.14817|issn=1538-7933}}</ref>
| |||